Tentative Settlement Approved in Abilify Cases
Defendants Otsuka Pharmaceuticals
and Bristol Meyer Squibb (BMS) have entered into a global settlement with 600 plaintiffs
in multi-district litigation over alleged side effects of the neuroleptic
medication Abilify (aripiprazole), prescribed for the treatment of
bipolar disorder, depression, and schizophrenia.If 90% of the plaintiffs agree to
the...
Legal Battle Over Abilify Side Effects Heats Up in Florida
The last four weeks have seen
significant developments in multidistrict litigation over the anti-psychotic
prescription medication Abilify
(aripiprazole) as both sides have filed motions, each side alleging the
other has interfered with pre-trial discovery.In January, defendants Otsuka Pharmaceuticals and Bristol-Meyer Squibb (BMS) asked Judge M. Casey Rogers to...
Study Indicates Link Between Antipsychotics and Death Among Young People
Last month, the journal JAMA
Psychiatry published
a study suggesting
that the use of antipsychotic medications may be fatal for children and
adolescents who have not been diagnosed with psychosis. The study focused on
patients who had been prescribed antipsychotic medications
for behavioral disorders, such as ADHD, bipolar, or depression. In the majority
of...
Abilify MyCite Vehicle Comes Under Fire Over Privacy Concerns
Almost one year ago, the FDA gave the green light to a “digital pill” that helps physicians to monitor patient compliance. The pill, developed by Proteus Digital Health, contains a small, ingestible transmitter that sends out an electronic signal via a sensor worn by the patient. This sensor then...
Failing to Reach a Settlement Abilify Bellwether Cases Head to Trial
Since the passing of a recent deadline to reach a global settlement in nearly 1,700 Abilify lawsuits (up from the 22 cases originally consolidated in 2016), counsel for defendants Otsuka Pharmaceuticals and Bristol-Meyer Squibb (BSM) and those for the plaintiffs have been working overtime to prepare for the test...
Deadline for Abilify Makers Less Than a Month Away
As of April of 2018, the were over 800 lawsuits pending against Otsuka Pharmaceuticals and its U.S. partner, Bristol-Meyer Squibb (BMS) over the psychoactive medication Abilify (aripiprizole). Plaintiffs allege that the drugmakers failed to warn patients and doctors about side effects that cause compulsive, uncontrollable behaviors, particularly gambling. Another alleged side...
Abililfy Manufacturers Are Off the Hook in Whistleblower Lawsuit
A six-year legal battle has finally ended for drugmakers Bristol-Meyer Squibb (BMS) and Otsuka as a judicial panel recently made a 2 to 1 decision not to revive a whistleblower lawsuit filed by two former employees.In U.S. v. Bristol Meyers Squibb Co., the Sixth Circuit ruled that the...
“Exponential Growth” Expected for the Antipsychotic Market; Meanwhile, Skilled Nursing Reduces Need for Such Drugs
A recent report from Allied Market Research has provided some news that is giving CEOs and shareholders in major pharmaceutical companies some reason to celebrate. Because of the rise in the number of patients suffering mental illness, primarily schizophrenia, the market for neuroleptic and anti-psychotic medications such as Abilify...
Abilify: New Study Indicates the Benefits Aren’t Worth the Risks
For some time, it has been known that the anti-depressant drug Abilify causes people who take it to behave in reckless, impulsive ways. In these situations, manufacturers of such harmful prescription medications argue that the benefits of the product outweigh the risks, often citing self-funded research studies. However, a...
Abilify Makers Join Forces With Manufacturer of the World’s First Ingestible Medical Monitor
Undeterred by a growing number of lawsuits over the antipsychotic medication Abilify, drugmaker Otsuka Pharmaceutical Company and its partners at Bristol-Meyers continue to seek new markets, promoting the drug for off-label uses ranging from autism to dementia and eating disorders.Bristol-Meyers even wound up paying out a $19.5 million...